| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.961 | 0.003 | 0.961 | Tyrosine kinase inhibitor | 0.946 0.004 DBMET03261 0.651 0.008 DBMET03264 0.905 0.004 DBMET03262 0.919 0.004 DBMET03263 | ||
| 0.911 | 0.002 | 0.911 | Janus tyrosine kinase 3 inhibitor | 0.851 0.003 DBMET03261 0.467 0.004 DBMET03264 0.77 0.003 DBMET03262 0.805 0.003 DBMET03263 | ||
| 0.843 | 0.01 | 0.852 | Antiinflammatory | 0.81 0.014 DBMET03261 0.798 0.015 DBMET03264 0.852 0.009 DBMET03262 0.829 0.012 DBMET03263 | DBMET03262 | |
| 0.835 | 0.005 | 0.835 | Toll-Like receptor 7 agonist | 0.76 0.006 DBMET03261 0.486 0.034 DBMET03264 0.809 0.005 DBMET03262 0.783 0.005 DBMET03263 | ||
| 0.83 | 0.005 | 0.83 | Toll-Like receptor agonist | 0.752 0.006 DBMET03261 0.476 0.037 DBMET03264 0.802 0.005 DBMET03262 0.776 0.005 DBMET03263 | ||
| 0.776 | 0.003 | 0.776 | Janus tyrosine kinase 2 inhibitor | 0.767 0.003 DBMET03261 0.417 0.005 DBMET03264 0.656 0.003 DBMET03262 0.673 0.003 DBMET03263 | ||
| 0.718 | 0.004 | 0.718 | CDC-like kinase 2 inhibitor | 0.462 0.008 DBMET03261 0.373 0.017 DBMET03264 0.495 0.006 DBMET03262 0.508 0.005 DBMET03263 | ||
| 0.702 | 0.002 | 0.702 | I kappa B kinase epsilon inhibitor | 0.42 0.003 DBMET03261 0.303 0.014 DBMET03264 0.564 0.002 DBMET03262 0.644 0.002 DBMET03263 | ||
| 0.694 | 0.004 | 0.694 | Death-associated protein kinase 3 inhibitor | 0.523 0.005 DBMET03261 0.488 0.007 DBMET03264 0.551 0.005 DBMET03262 0.559 0.005 DBMET03263 | ||
| 0.68 | 0.004 | 0.68 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.411 0.005 DBMET03261 0.338 0.009 DBMET03264 0.447 0.005 DBMET03262 0.466 0.005 DBMET03263 | ||
| 0.666 | 0.003 | 0.666 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.579 0.004 DBMET03261 0.582 0.004 DBMET03264 0.596 0.003 DBMET03262 0.592 0.003 DBMET03263 | ||
| 0.648 | 0.004 | 0.648 | TRKC antagonist | 0.534 0.005 DBMET03261 0.439 0.009 DBMET03264 0.575 0.005 DBMET03262 0.564 0.005 DBMET03263 | ||
| 0.648 | 0.005 | 0.648 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.391 0.019 DBMET03261 0.336 0.032 DBMET03264 0.432 0.013 DBMET03262 0.437 0.013 DBMET03263 | ||
| 0.619 | 0.004 | 0.619 | Protein kinase C nu inhibitor | 0.416 0.009 DBMET03261 0.344 0.017 DBMET03264 0.453 0.006 DBMET03262 0.434 0.007 DBMET03263 | ||
| 0.618 | 0.005 | 0.618 | CDC-like kinase 4 inhibitor | 0.358 0.019 DBMET03261 0.206 0.064 DBMET03264 0.404 0.014 DBMET03262 0.441 0.01 DBMET03263 | ||
| 0.59 | 0.005 | 0.59 | Clk dual-specificity kinase inhibitor | 0.36 0.026 DBMET03261 0.184 0.089 DBMET03264 0.398 0.02 DBMET03262 0.427 0.015 DBMET03263 | ||
| 0.588 | 0.005 | 0.588 | RET inhibitor | 0.312 0.02 DBMET03261 0.35 0.015 DBMET03262 0.351 0.014 DBMET03263 | ||
| 0.589 | 0.013 | 0.61 | Immunomodulator | 0.506 0.022 DBMET03261 0.61 0.01 DBMET03262 0.513 0.021 DBMET03263 | DBMET03262 | |
| 0.583 | 0.006 | 0.583 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.357 0.034 DBMET03261 0.189 0.1 DBMET03264 0.381 0.028 DBMET03262 0.446 0.019 DBMET03263 | ||
| 0.577 | 0.008 | 0.577 | Dyrk kinase inhibitor | 0.345 0.038 DBMET03261 0.166 0.121 DBMET03264 0.37 0.032 DBMET03262 0.426 0.022 DBMET03263 | ||
| 0.57 | 0.017 | 0.636 | Immunosuppressant | 0.597 0.014 DBMET03261 0.477 0.039 DBMET03264 0.636 0.009 DBMET03262 0.575 0.016 DBMET03263 | DBMET03262 | |
| 0.546 | 0.002 | 0.546 | Janus tyrosine kinase 1 inhibitor | 0.48 0.002 DBMET03261 0.36 0.003 DBMET03264 0.428 0.002 DBMET03262 0.441 0.002 DBMET03263 | ||
| 0.548 | 0.004 | 0.548 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.425 0.009 DBMET03261 0.217 0.06 DBMET03264 0.446 0.007 DBMET03262 0.442 0.007 DBMET03263 | ||
| 0.524 | 0.004 | 0.524 | Antipruritic | 0.446 0.005 DBMET03261 0.494 0.005 DBMET03262 0.501 0.004 DBMET03263 | ||
| 0.486 | 0.003 | 0.486 | Tyk2 inhibitor | 0.337 0.004 DBMET03261 0.241 0.006 DBMET03264 0.355 0.004 DBMET03262 0.368 0.004 DBMET03263 | ||
| 0.469 | 0.004 | 0.469 | TRKB antagonist | 0.342 0.007 DBMET03261 0.186 0.029 DBMET03264 0.379 0.005 DBMET03262 0.353 0.006 DBMET03263 | ||
| 0.459 | 0.006 | 0.459 | Tyrosine-protein kinase receptor antagonist | 0.207 0.038 DBMET03261 0.319 0.015 DBMET03262 0.186 0.046 DBMET03263 | ||
| 0.464 | 0.013 | 0.464 | Growth factor antagonist | 0.154 0.067 DBMET03261 0.167 0.059 DBMET03262 0.216 0.042 DBMET03263 | ||
| 0.43 | 0.006 | 0.43 | Protein kinase (CK1) inhibitor | 0.237 0.029 DBMET03261 0.119 0.092 DBMET03264 0.267 0.023 DBMET03262 0.303 0.017 DBMET03263 | ||
| 0.413 | 0.005 | 0.413 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.192 0.03 DBMET03261 0.215 0.024 DBMET03262 0.205 0.027 DBMET03263 | ||
| 0.412 | 0.005 | 0.412 | Abl kinase inhibitor | 0.191 0.03 DBMET03261 0.214 0.024 DBMET03262 0.203 0.027 DBMET03263 | ||
| 0.397 | 0.004 | 0.397 | Cyclin-dependent kinase 8 inhibitor | 0.245 0.017 DBMET03261 0.127 0.108 DBMET03264 0.319 0.007 DBMET03262 0.223 0.024 DBMET03263 | ||
| 0.375 | 0.005 | 0.375 | Protein kinase A inhibitor | 0.217 0.011 DBMET03261 0.082 0.059 DBMET03264 0.269 0.008 DBMET03262 0.219 0.011 DBMET03263 | ||
| 0.368 | 0.003 | 0.368 | Leucine-rich repeat kinase 2 inhibitor | 0.179 0.013 DBMET03261 0.217 0.008 DBMET03262 0.215 0.008 DBMET03263 | ||
| 0.378 | 0.02 | 0.378 | EphB2 antagonist | 0.287 0.04 DBMET03261 0.301 0.035 DBMET03262 0.266 0.049 DBMET03263 | ||
| 0.357 | 0.005 | 0.357 | Fibroblast growth factor 1 antagonist | 0.201 0.016 DBMET03261 0.22 0.013 DBMET03264 0.216 0.013 DBMET03262 0.237 0.01 DBMET03263 | ||
| 0.392 | 0.063 | 0.392 | MAP kinase kinase 6 inhibitor | 0.286 0.149 DBMET03261 0.268 0.169 DBMET03262 0.256 0.182 DBMET03263 | ||
| 0.337 | 0.012 | 0.337 | Glycogen synthase kinase-3 alpha inhibitor | 0.151 0.066 DBMET03261 0.221 0.035 DBMET03262 0.259 0.024 DBMET03263 | ||
| 0.35 | 0.038 | 0.486 | Tumour necrosis factor alpha release inhibitor | 0.433 0.022 DBMET03261 0.229 0.086 DBMET03264 0.448 0.02 DBMET03262 0.486 0.015 DBMET03263 | DBMET03263 | |
| 0.312 | 0.004 | 0.312 | Rho-associated kinase I inhibitor | 0.086 0.041 DBMET03261 0.101 0.031 DBMET03262 0.118 0.022 DBMET03263 | ||
| 0.366 | 0.064 | 0.366 | Angiogenesis inhibitor | 0.256 0.119 DBMET03261 0.279 0.104 DBMET03262 0.286 0.1 DBMET03263 | ||
| 0.307 | 0.005 | 0.307 | Rho-associated kinase inhibitor | 0.107 0.032 DBMET03261 0.11 0.03 DBMET03262 0.129 0.024 DBMET03263 | ||
| 0.313 | 0.031 | 0.313 | MAP kinase kinase 2 inhibitor | 0.165 0.108 DBMET03261 0.185 0.092 DBMET03262 0.146 0.125 DBMET03263 | ||
| 0.271 | 0.005 | 0.271 | I kappa B kinase inhibitor | 0.143 0.018 DBMET03261 0.194 0.008 DBMET03262 0.253 0.005 DBMET03263 | ||
| 0.279 | 0.015 | 0.329 | Aurora-A kinase inhibitor | 0.127 0.051 DBMET03261 0.329 0.01 DBMET03264 0.139 0.044 DBMET03262 0.199 0.025 DBMET03263 | DBMET03264 | |
| 0.291 | 0.029 | 0.291 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.194 0.184 DBMET03261 | ||
| 0.277 | 0.018 | 0.277 | Phosphodiesterase inhibitor | 0.233 0.026 DBMET03261 0.254 0.021 DBMET03262 0.255 0.021 DBMET03263 | ||
| 0.275 | 0.018 | 0.275 | Aurora-B kinase inhibitor | 0.101 0.08 DBMET03261 0.134 0.054 DBMET03262 0.207 0.029 DBMET03263 | ||
| 0.255 | 0.023 | 0.255 | Lck kinase inhibitor | 0.146 0.068 DBMET03261 0.166 0.056 DBMET03262 0.158 0.06 DBMET03263 | ||
| 0.251 | 0.026 | 0.251 | Tyrosine-protein kinase receptor FLT3 inhibitor | |||
| 0.271 | 0.047 | 0.271 | MAP-kinase-activated kinase 5 inhibitor | 0.186 0.122 DBMET03261 0.206 0.096 DBMET03262 0.188 0.12 DBMET03263 | ||
| 0.253 | 0.029 | 0.253 | MAP kinase kinase 3 inhibitor | 0.191 0.151 DBMET03261 0.191 0.151 DBMET03262 0.205 0.108 DBMET03263 | ||
| 0.222 | 0.005 | 0.222 | Phosphodiesterase III inhibitor | 0.17 0.008 DBMET03261 0.076 0.039 DBMET03264 0.164 0.009 DBMET03262 0.201 0.006 DBMET03263 | ||
| 0.218 | 0.005 | 0.218 | Fibroblast growth factor 3 antagonist | 0.079 0.051 DBMET03261 0.099 0.033 DBMET03262 0.123 0.023 DBMET03263 | ||
| 0.258 | 0.046 | 0.258 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | |||
| 0.241 | 0.038 | 0.241 | Src kinase inhibitor | 0.134 0.095 DBMET03261 0.144 0.088 DBMET03262 0.146 0.086 DBMET03263 | ||
| 0.247 | 0.053 | 0.247 | ErbB-1 antagonist | |||
| 0.189 | 0.012 | 0.221 | Phosphodiesterase 4D inhibitor | 0.221 0.009 DBMET03261 0.194 0.012 DBMET03262 0.201 0.011 DBMET03263 | DBMET03261 | |
| 0.226 | 0.05 | 0.226 | LIM domain kinase 1 inhibitor | |||
| 0.178 | 0.006 | 0.178 | Tyrosine-protein kinase EMT inhibitor | 0.093 0.02 DBMET03261 0.103 0.017 DBMET03262 0.093 0.02 DBMET03263 | ||
| 0.191 | 0.02 | 0.288 | Bronchodilator | 0.288 0.01 DBMET03261 0.265 0.012 DBMET03262 0.21 0.017 DBMET03263 | DBMET03261 | |
| 0.18 | 0.024 | 0.18 | MAP kinase kinase 4 inhibitor | 0.159 0.047 DBMET03261 0.168 0.035 DBMET03262 0.143 0.078 DBMET03263 | ||
| 0.151 | 0.007 | 0.162 | Phosphodiesterase 4C inhibitor | 0.15 0.007 DBMET03261 0.14 0.008 DBMET03262 0.162 0.006 DBMET03263 | DBMET03263 | |
| 0.166 | 0.022 | 0.166 | Activin receptor-like kinase 4 inhibitor | 0.106 0.074 DBMET03261 0.103 0.08 DBMET03262 0.113 0.063 DBMET03263 | ||
| 0.16 | 0.018 | 0.16 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.112 0.037 DBMET03261 0.142 0.025 DBMET03262 0.079 0.072 DBMET03263 | ||
| 0.181 | 0.046 | 0.181 | Ribosomal protein S6 kinase inhibitor | |||
| 0.172 | 0.04 | 0.172 | MAP kinase kinase inhibitor | 0.116 0.078 DBMET03261 0.12 0.074 DBMET03262 | ||
| 0.156 | 0.031 | 0.156 | Death-associated protein kinase 1 inhibitor | 0.122 0.107 DBMET03263 | ||
| 0.135 | 0.013 | 0.135 | Protein kinase B alpha inhibitor | |||
| 0.127 | 0.005 | 0.127 | Fibroblast growth factor 4 antagonist | 0.085 0.015 DBMET03261 0.077 0.021 DBMET03264 0.086 0.015 DBMET03262 0.091 0.012 DBMET03263 | ||
| 0.165 | 0.049 | 0.165 | Cyclin-dependent kinase inhibitor | 0.101 0.09 DBMET03262 | ||
| 0.127 | 0.012 | 0.127 | Phosphodiesterase 4A inhibitor | 0.127 0.012 DBMET03261 0.11 0.014 DBMET03262 0.119 0.013 DBMET03263 | ||
| 0.126 | 0.013 | 0.126 | MAP3K7 inhibitor | 0.081 0.039 DBMET03261 0.092 0.028 DBMET03262 0.074 0.048 DBMET03263 | ||
| 0.168 | 0.057 | 0.168 | CDC-like kinase 1 inhibitor | 0.109 0.108 DBMET03263 | ||
| 0.132 | 0.021 | 0.132 | Protein kinase B gamma inhibitor | 0.066 0.063 DBMET03262 | ||
| 0.119 | 0.016 | 0.119 | Protein kinase B beta inhibitor | 0.077 0.046 DBMET03261 0.086 0.036 DBMET03262 0.073 0.052 DBMET03263 | ||
| 0.125 | 0.027 | 0.125 | ALK inhibitor | 0.077 0.063 DBMET03261 0.083 0.055 DBMET03262 0.092 0.046 DBMET03263 | ||
| 0.156 | 0.063 | 0.156 | Protein-tyrosine kinase Lyn inhibitor | |||
| 0.154 | 0.063 | 0.154 | Activin receptor-like kinase 2 inhibitor | |||
| 0.123 | 0.033 | 0.123 | Hepatocyte growth factor antagonist | 0.089 0.064 DBMET03263 | ||
| 0.139 | 0.049 | 0.139 | Glycogen synthase kinase-3 beta inhibitor | 0.113 0.066 DBMET03263 | ||
| 0.137 | 0.051 | 0.137 | Glycogen synthase kinase-3 inhibitor | 0.109 0.071 DBMET03263 | ||
| 0.109 | 0.024 | 0.109 | Focal adhesion kinase 1 inhibitor | 0.079 0.05 DBMET03264 0.072 0.059 DBMET03262 0.096 0.033 DBMET03263 | ||
| 0.123 | 0.038 | 0.123 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | |||
| 0.111 | 0.028 | 0.111 | MAP kinase 10 inhibitor | 0.071 0.063 DBMET03262 | ||
| 0.102 | 0.02 | 0.102 | Phosphatidylinositol kinase inhibitor | 0.066 0.036 DBMET03262 0.086 0.026 DBMET03263 | ||
| 0.099 | 0.02 | 0.099 | Phosphatidylinositol 3-kinase delta inhibitor | 0.05 0.046 DBMET03262 0.072 0.029 DBMET03263 | ||
| 0.127 | 0.057 | 0.127 | Protein kinase (CK2) alpha inhibitor | 0.119 0.063 DBMET03263 | ||
| 0.132 | 0.062 | 0.132 | Vascular endothelial growth factor antagonist | |||
| 0.091 | 0.022 | 0.091 | MAP kinase kinase 10 inhibitor | |||
| 0.103 | 0.037 | 0.103 | AXL receptor tyrosine kinase inhibitor | 0.076 0.067 DBMET03261 0.096 0.043 DBMET03262 | ||
| 0.13 | 0.066 | 0.13 | Protein kinase (CK1) delta inhibitor | |||
| 0.099 | 0.036 | 0.099 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.071 0.059 DBMET03261 0.078 0.052 DBMET03262 0.067 0.065 DBMET03263 | ||
| 0.091 | 0.028 | 0.091 | Cyclin A2 inhibitor | |||
| 0.128 | 0.065 | 0.128 | Epidermal growth factor receptor kinase inhibitor | |||
| 0.119 | 0.057 | 0.119 | Polo-like kinase-4 inhibitor | |||
| 0.107 | 0.046 | 0.107 | Protein kinase C delta inhibitor | 0.094 0.058 DBMET03262 | ||
| 0.141 | 0.084 | 0.284 | Heat shock protein 90 antagonist | 0.169 0.056 DBMET03261 0.284 0.013 DBMET03262 0.17 0.055 DBMET03263 | DBMET03262 | |
| 0.076 | 0.02 | 0.076 | Phosphodiesterase II inhibitor | 0.06 0.032 DBMET03261 0.061 0.031 DBMET03262 0.055 0.039 DBMET03263 | ||
| 0.088 | 0.034 | 0.088 | Check point kinase 1 inhibitor | 0.066 0.049 DBMET03261 0.073 0.043 DBMET03262 0.062 0.055 DBMET03263 | ||
| 0.084 | 0.029 | 0.084 | Cyclin A inhibitor | |||
| 0.093 | 0.039 | 0.093 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | |||
| 0.144 | 0.091 | 0.144 | Polo-like kinase-3 inhibitor | |||
| 0.08 | 0.029 | 0.08 | Raf kinase B inhibitor | 0.054 0.046 DBMET03263 | ||
| 0.071 | 0.022 | 0.071 | Protein kinase C theta inhibitor | |||
| 0.113 | 0.064 | 0.113 | Vascular endothelial growth factor 2 antagonist | |||
| 0.077 | 0.029 | 0.077 | Adenosine A1 receptor antagonist | 0.069 0.034 DBMET03261 0.065 0.036 DBMET03262 0.062 0.038 DBMET03263 | ||
| 0.067 | 0.02 | 0.067 | Phosphodiesterase 2A inhibitor | 0.051 0.033 DBMET03261 0.052 0.032 DBMET03262 0.047 0.04 DBMET03263 | ||
| 0.131 | 0.084 | 0.131 | Vascular endothelial growth factor 3 antagonist | |||
| 0.134 | 0.088 | 0.134 | MAP3K9 inhibitor | |||
| 0.086 | 0.041 | 0.086 | Raf kinase inhibitor | |||
| 0.069 | 0.025 | 0.069 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.052 0.042 DBMET03262 0.059 0.034 DBMET03263 | ||
| 0.124 | 0.081 | 0.124 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.105 | 0.062 | 0.105 | MAP kinase kinase kinase inhibitor | |||
| 0.092 | 0.051 | 0.153 | Phosphodiesterase IV inhibitor | 0.153 0.022 DBMET03261 0.133 0.028 DBMET03262 0.151 0.022 DBMET03263 | DBMET03261 | |
| 0.082 | 0.042 | 0.082 | MAP kinase kinase 7 inhibitor | |||
| 0.067 | 0.028 | 0.067 | Bruton tyrosine kinase inhibitor | |||
| 0.089 | 0.053 | 0.089 | Bcr-Abl kinase inhibitor | |||
| 0.063 | 0.026 | 0.063 | mTOR inhibitor | 0.052 0.036 DBMET03262 0.046 0.044 DBMET03263 | ||
| 0.092 | 0.056 | 0.124 | Pim-3 kinase inhibitor | 0.098 0.047 DBMET03261 0.124 0.029 DBMET03262 | DBMET03262 | |
| 0.126 | 0.092 | 0.126 | Aurora-C kinase inhibitor | |||
| 0.041 | 0.009 | 0.041 | LIM domain kinase 2 inhibitor | |||
| 0.135 | 0.103 | 0.135 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | |||
| 0.15 | 0.12 | 0.15 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | |||
| 0.098 | 0.067 | 0.098 | Check point kinase 2 inhibitor | |||
| 0.085 | 0.055 | 0.085 | ErbB-3 antagonist | |||
| 0.077 | 0.047 | 0.093 | Adenosine A3 receptor antagonist | 0.093 0.031 DBMET03261 0.085 0.037 DBMET03262 | DBMET03261 | |
| 0.07 | 0.04 | 0.07 | Adenosine A2 receptor antagonist | |||
| 0.085 | 0.056 | 0.085 | mTOR complex 2 inhibitor | |||
| 0.102 | 0.075 | 0.102 | CDC-like kinase 3 inhibitor | |||
| 0.142 | 0.116 | 0.142 | Cyclin-dependent kinase 3 inhibitor | |||
| 0.069 | 0.045 | 0.069 | Protein kinase C alpha inhibitor | |||
| 0.092 | 0.071 | 0.136 | Protein kinase (CK2) inhibitor | 0.089 0.074 DBMET03262 0.136 0.039 DBMET03263 | DBMET03263 | |
| 0.077 | 0.059 | 0.093 | Phosphodiesterase 3A inhibitor | 0.093 0.039 DBMET03263 | DBMET03263 | |
| 0.068 | 0.05 | 0.068 | I kappa B kinase 1 inhibitor | |||
| 0.13 | 0.114 | 0.13 | Protein kinase (CK1) gamma 3 inhibitor | |||
| 0.084 | 0.07 | 0.084 | Phosphodiesterase I inhibitor | 0.08 0.077 DBMET03261 | ||
| 0.059 | 0.045 | 0.059 | Adenosine A2a receptor antagonist | |||
| 0.034 | 0.02 | 0.046 | Transforming growth factor beta 2 antagonist | 0.032 0.025 DBMET03261 0.031 0.03 DBMET03262 0.046 0.008 DBMET03263 | DBMET03263 | |
| 0.093 | 0.081 | 0.093 | Granulocyte macrophage colony stimulating factor antagonist | |||
| 0.07 | 0.06 | 0.07 | ErbB-4 antagonist | |||
| 0.047 | 0.037 | 0.047 | Adenosine A2b receptor antagonist | |||
| 0.021 | 0.013 | 0.021 | Histone-lysine N-methyltransferase EZH2 inhibitor | |||
| 0.078 | 0.071 | 0.078 | Transforming growth factor beta 3 antagonist | |||
| 0.098 | 0.091 | 0.098 | c-Src kinase inhibitor | |||
| 0.077 | 0.071 | 0.077 | Epidermal growth factor antagonist | |||
| 0.125 | 0.119 | 0.125 | MAP kinase 3 inhibitor | |||
| 0.094 | 0.09 | 0.094 | MAP kinase 13 inhibitor | |||
| 0.018 | 0.016 | 0.036 | Integrin alphaVbeta1 antagonist | 0.036 0.005 DBMET03264 0.021 0.011 DBMET03262 | DBMET03264 | |
| 0.031 | 0.029 | 0.031 | ATR kinase inhibitor | |||
| 0.111 | 0.109 | 0.111 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.011 | 0.01 | 0.011 | Purine nucleoside phosphorylase inhibitor | 0.011 0.01 DBMET03262 | ||
| 0.066 | 0.065 | 0.066 | ErbB-2 antagonist | |||
| 0.053 | 0.054 | 0.06 | Heat shock protein 90 beta antagonist | 0.06 0.04 DBMET03262 | DBMET03262 | |
| 0.046 | 0.054 | 0.069 | Pim-2 kinase inhibitor | 0.052 0.042 DBMET03261 0.069 0.025 DBMET03262 | DBMET03262 | |
| 0.036 | 0.043 | 0.039 | Phosphodiesterase 3B inhibitor | 0.039 0.038 DBMET03263 | DBMET03263 | |
| 0.059 | 0.068 | 0.065 | Transforming growth factor antagonist | 0.065 0.056 DBMET03263 | DBMET03263 | |
| 0.074 | 0.091 | 0.104 | Pim-1 kinase inhibitor | 0.089 0.069 DBMET03261 0.104 0.054 DBMET03262 0.09 0.068 DBMET03263 | DBMET03262 | |
| 0.054 | 0.075 | 0.088 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.088 0.035 DBMET03264 | DBMET03264 | |
| 0.083 | 0.106 | 0.094 | mTOR complex 1 inhibitor | 0.094 0.075 DBMET03262 | DBMET03262 | |
| 0.05 | 0.075 | 0.062 | Syk tyrosine kinase inhibitor | 0.062 0.058 DBMET03262 | DBMET03262 | |
| 0.115 | 0.147 | 0.129 | Pregnane X receptor agonist | 0.123 0.12 DBMET03261 0.129 0.101 DBMET03262 | DBMET03262 | |
| 0.133 | 0.185 | 0.204 | Growth factor agonist | 0.151 0.14 DBMET03262 0.204 0.059 DBMET03263 | DBMET03263 | |
| 0.021 | 0.094 | 0.049 | Adenosine deaminase inhibitor | 0.049 0.031 DBMET03261 0.045 0.035 DBMET03262 | DBMET03261 | |
| 0.07 | 0.148 | 0.098 | Alpha 2d adrenoreceptor antagonist | 0.098 0.053 DBMET03261 0.088 0.075 DBMET03262 0.089 0.073 DBMET03263 | DBMET03261 | |
| 0.047 | 0.126 | 0.067 | MAP kinase kinase 8 inhibitor | 0.067 0.05 DBMET03262 | DBMET03262 | |
| 0.008 | 0.112 | 0.097 | Somatostatin 3 antagonist | 0.097 0.004 DBMET03264 | DBMET03264 | |
| 0.084 | 0.216 | 0.126 | Heat shock protein 90 alpha antagonist | 0.126 0.118 DBMET03262 | DBMET03262 | |
| 0.082 | 0.264 | 0.131 | Tumour necrosis factor antagonist | 0.131 0.126 DBMET03263 | DBMET03263 | |
| 0.1 | 0.387 | 0.285 | Sodium/bile acid cotransporter inhibitor | 0.241 0.138 DBMET03261 0.285 0.093 DBMET03262 | DBMET03262 | |
| 0.049 | 0.372 | 0.162 | Platelet antagonist | 0.162 0.132 DBMET03261 | DBMET03261 | |
| 0.003 | 0.731 | 0.174 | Somatostatin 2 antagonist | 0.174 0.004 DBMET03264 | DBMET03264 | |
| 0.004 | 0.737 | 0.151 | Somatostatin 1 antagonist | 0.151 0.005 DBMET03264 | DBMET03264 | |
| 0.004 | 0.772 | 0.154 | Somatostatin 4 antagonist | 0.154 0.004 DBMET03264 | DBMET03264 | |
| 0.002 | 0.902 | 0.136 | Somatostatin 5 antagonist | 0.136 0.005 DBMET03264 | DBMET03264 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |